[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-transplant-failure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-transplant-failure":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,68,90],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100546773","prospective-multicenter-research-on-donor-and-recipient-management-strategies-to-improve-lung-transplant-outcomes-100546773",false,"NCT06399302","Prospective Multicenter Research on Donor and Recipient Management Strategies to Improve Lung Transplant Outcomes","Prospective Multicenter Research on Donor and Recipient Management Strategies to Improve Lung Transplant Outcomes: PROMISE-Lung Study","PROMISE","Inclusion Criteria:\n\n1. Able to understand and provide informed consent\n2. ≥ 18 years of age at the time of written informed consent\n3. Anticipated listing or listed for a single or bilateral cadaveric donor lung transplant or having received a lung transplant within 30 days\n\n   * Participants undergoing repeat lung transplantation or multi-organ transplantation are eligible if they meet the inclusion\u002Fexclusion criteria.\n\nExclusion Criteria:\n\n1. Unwillingness of a participant or legally authorized representative (LAR) to give written informed consent or comply with study protocol\n2. Pregnancy or plans to become pregnant\n3. Past or current medical problems or findings from physical examination or laboratory testing, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.","ALL","18 Years",{"count":20,"type":21},2600,"ESTIMATED","OBSERVATIONAL","This project aims to collect detailed clinical data, blood samples, and patient-reported outcomes from 2,600 lung transplant candidates, donors, and recipients at Lung Transplant Centers. The goal is to create a robust resource for various research objectives, including studying the impact of variations in donor and medical practices on clinical outcomes. The project also seeks to identify serum biomarkers associated with or predictive of specific post-transplant complications and conditions.",[25,26,27,28],"Lung Transplant; Complications","Lung Transplant; Infection or Inflammation","Lung Transplant Rejection","Lung Transplant Failure","RECRUITING","2026-05-07",{"date":32,"type":33},"2026-05-11","ACTUAL",{"date":35,"type":33},"2024-09-03",{"date":37,"type":21},"2027-06-30",{"name":39,"class":40},"Duke University","OTHER",19,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100536017","prone-positioning-in-neurologically-deceased-potential-organ-donors-to-improve-donor-lung-function-and-lung-transplant-recipient-outcomes-100536017","NCT06259357","Prone Positioning in Neurologically Deceased Potential Organ Donors to Improve Donor Lung Function and Lung Transplant Recipient Outcomes","Prone Positioning in Neurologically Deceased Potential Organ Donors to Improve Donor Lung Function and Lung Transplant Recipient Outcomes (P-POD) Pilot Trial","P-POD","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Neurological determination of death at time of study entry\n3. Consent to organ donation\n4. Eligible for organ donation as confirmed by Trillium Gift of Life Network Coordinator\n\nExclusion Criteria:\n\n1. Open chest or abdominal wounds on the ventral body surface\n2. Absolute contraindication to lung transplantation on initial eligibility screening:\n\n   * Infection i. Positive HIV, HbsAg, Human T-lymphotropic virus-I\u002FII test results ii. Positive West Nile Virus (WNV PCR) test results iii. Rabies diagnosis or within the last 6 months bitten by an animal proven to have rabies iv. Active endocarditis v. Active encephalitis or meningitis of unknown etiology vi. Active disseminated tuberculosis vii. Viral hemorrhagic fever including Ebola or known exposure to person with Ebola viii. COVID-19 presumptive or confirmed positive in the last 14 days\n   * Malignancy i. Donors with active cancer (donors receiving chemotherapy or radiation therapy or palliative cancer care within the last 5 years); excluding skin and primary brain tumors and prostate cancers.\n\nii. Donors with a history of the following malignancies:\n\n* Lung Cancer\n* Choriocarcinoma\n* Breast Cancer\n* Colon Cancer within the last 10 years iii. Donors with active or past history of melanoma o Clinician decision that prone position is contraindicated",{"count":51,"type":21},40,"INTERVENTIONAL",[54],"NA","The purpose of this study is to determine the practicality of performing a future, large-scale study. The future study will look at the effect of mechanical ventilation in neurologically deceased (brain-dead) lung donors who are positioned to lay flat on their stomach (prone position), compared to donors who are positioned to lay flat on their back (supine position). The study will also look at the potential impact of prone positioning of the donor on transplant recipients of the study organs.\n\nThe investigators are doing this study because the investigators want to increase the availability of donor lungs for lung transplant. Lung transplant is a life-saving treatment for individuals with lung disease, but there are not enough donated lungs to meet demand. Researchers are looking for better ways of preventing donated lungs from becoming unsuitable for transplant. Because of this, the goal of our study is to test whether prone positioning in neurologically deceased (brain-dead) lung donors can improve donor lung function and decrease complications, potentially increasing the number of donor lungs that can be used for transplant.",[28],"NOT_YET_RECRUITING","2024-12-03",{"date":60,"type":33},"2024-12-04",{"date":62,"type":21},"2025-01-02",{"date":64,"type":21},"2026-08-01",{"name":66,"class":40},"Lorenzo delSorbo",1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":52,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":67},"100479743","cytokine-filtration-in-lung-transplantation-a-swedish-national-study-glusorb-100479743","NCT05526950","Cytokine Filtration in Lung Transplantation: A Swedish National Study (GLUSorb)","Cytokine Filtration in Lung Transplantation - a Randomised, Controlled, Multicentre Clinical Trial (GLUSorb)","Inclusion Criteria:\n\n• Eligibility to undergo double lung transplantation at either trial site\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years\n2. Previous organ transplantation\n3. Presence of any conditions at the time of surgery that require immunosuppressive therapy. Immunosuppressive therapy is defined as:\n\n   1. Cyclosporine, Tacrolimus, Everolimus, or Sirolimus, minimum 1 month of treatment prior to transplantation and active treatment at the time of transplantation.\n   2. Any form of antibody-based treatment that is known for having an immunomodulatory effect taken up to 1 week before transplantation.\n4. Non-consent","80 Years",{"count":77,"type":21},116,[54],"Lung transplantation (LTx) remains the gold standard for treating patients with irreversible end-stage pulmonary disease. Of the major organs transplanted, survival in LTx recipients remains the lowest (mean 5 years). Despite improvements, primary graft dysfunction (PGD), as defined by respiratory insufficiency and edema up to 72 hours post LTx, remains the leading cause of early mortality and contributes to the development of chronic lung allograft dysfunction (CLAD) which is the leading cause of late mortality. PGD develops within the first 72 hours after LTx. The development of CLAD increases quickly with cumulative incidence of 40-80 % within the first 3-5 years. There is a general lack of efficient treatments for PGD and CLAD. Prevention of PGD is therefore of crucial importance and has a direct impact on survival.\n\nThe present study is a randomized controlled study which aims to compare patients undergoing LTx with and without the utilization of cytokine adsorption.",[28,25],"2023-09-14",{"date":83,"type":33},"2023-09-18",{"date":85,"type":33},"2023-09-07",{"date":87,"type":21},"2029-12-31",{"name":89,"class":40},"Lund University Hospital",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":97,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":52,"phases":100,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":67},"100426771","diagnostic-and-prognostic-biomarkers-of-transplant-dysfunction-in-the-context-of-lung-transplantation-100426771","NCT04837339","Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation","DATACOL","Inclusion Criteria:\n\n* Men or women over 15 years of age\n* Suffering from a lung condition requiring a transplant planned at Foch Hospital or being followed up at Foch Hospital following a lung transplant\n* Have signed the informed consent form and for patients aged 15 to 18 years that the person(s) exercising parental authority has\u002Fhave signed the informed consent.\n* Be affiliated with a Health Insurance plan.\n\nExclusion Criteria:\n\n* Pregnant, parturient and\u002For lactating woman\n* Hemoglobin level less than or equal to 8g\u002Fdl\n* Persons of full age who are subject to a legal protection measure or who are unable to express their consent\n* Persons under the protection of justice\n* Not being able to follow the study requirements for geographical, social or psychological reasons\n* Patient refusal.","15 Years",{"count":99,"type":21},900,[54],"Transplant results vary considerably from one organ to another. Lung transplantation has poorer long-term outcomes than other solid organ transplants, with a current median post-transplant survival of 6.0 years. Allograft rejection remains the leading cause of morbidity and mortality in all organ groups and is the leading cause of death, accounting for more than 40% of deaths beyond the first year after lung transplantation.\n\nEach dysfunctions impacts the fate of the graft and therefore the survival of the recipient. Their early and precise diagnosis is therefore a major issue. The identification of the pathophysiological mechanisms underlying these different subtypes of dysfunction (transcriptomics, polymorphism of target genes of the immune system or tissue repair, cell phenotyping) is an essential step. It can only be done on the basis of a collection of samples linked to a clinical database allowing to contextualize each sample.",[27,28,25,103],"Lung Transplant Failure and Rejection",[95],"2022-08-02",{"date":107,"type":33},"2022-08-03",{"date":109,"type":33},"2022-03-17",{"date":111,"type":21},"2037-03",{"name":113,"class":40},"Hopital Foch"]